SAB Biotherapeutics Inc
NASDAQ:SABS 4:00:00 PM EDT
| Market Cap (Intraday) | 30.17M |
| Current PE | N/A |
| Forward PE | N/A |
| 2yr Forward PE | N/A |
| 10-Day MA | $0.69 |
| 50-Day MA | $0.82 |
| 200-Day MA | $1.18 |
SAB Biotherapeutics Inc Stock, NASDAQ:SABS
2100 East 54th Street North, Suite 202, Sioux Falls, South Dakota 57104
United States of America
Phone: +1.605.679.6980
Number of Employees: 139
Description
SAB Biotherapeutics, Inc. is a clinical-stage, biopharmaceutical company. It is engaged in advancing a new class of immunotherapies leveraging fully-human polyclonal antibodies. The firm produces human polyclonal immunotherapies and its versatile DiversitAb platform is applicable for unmet needs in human diseases. SAB Biotherapeutics was founded by Eddie J. Sullivan and Christine E. Hamilton and is headquartered in Sioux Falls, SD.